RUBINSTEIN JULIE sold $920K of ADPT
RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $25.81 ($25.35–$26.41, $0.92M total) across 4 trades over 2026-10-09 to 2026-10-13 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale may cause short‑term price pressure but is unlikely to affect long‑term valuation.
Market read
Primary insider sale filing; modest relevance for traders monitoring insider activity.
What to watch
The 10b5‑1 plan indicates pre‑planned execution, reducing the signaling strength.
Background
SEC Form 4 filings disclose insider transactions. This filing reports a multi‑day sale by the company's President and COO.
Ticker impact
Form 4 filing shows President and COO Julie Rubinstein sold 35,643 shares for $919.9K via a 10b5‑1 plan.
likely modest pressure as the market prices in the insider sell.
The sale is a primary disclosure of a sizable insider transaction, albeit under $1M, which can prompt short‑term selling pressure.
Market effects
Minimal impact on the biotech sector; insider sales are routine.
No broader regional effect.
Limited to Adaptive Biotechnologies shareholders.
Counterpoint
The sale could be a routine liquidity event unrelated to fundamentals.
Key entities
- CompanyAdaptive Biotechnologies Corp
US‑listed biotech firm (NASDAQ: ADPT).
- ExecutiveJulie Rubinstein
President and COO of Adaptive Biotechnologies.
